OFIX at a glance
Orthofix Medical Inc. (OFIX, SEC CIK 884624) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Orthofix Medical Inc. (OFIX) reported revenue of $822.3 million (up 2.9% from FY2024) and a net loss of $92.2 million. Diluted EPS was -$2.33.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Orthofix Medical Inc. (OFIX) shares worth $111.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Juniper Investment Company, LLC on November 11, 2026 of 14,803 shares at $7.04 per share.
- In the last 90 days, OFIX insiders reported 4 open-market purchases ($7.8M) and 5 open-market sales ($2.7M) on Form 4, a net purchase of $5.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $822.3M
- +2.9% vs prior year
- Insiders · 90 days
- 4 buys · 5 sells
- Net +$5.1M
- 13F holders
- 22 funds
- $111.9M · −3 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 7.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $207.9M, up 1.1% YoY from $205.6M
- Operating margin 0.7% vs (8.3%) YoY, net loss margin (2.9%) vs (11.1%)
- Best segment Global Limb Reconstruction, $36.4M, up 8.5%; worst Spinal Implants, Biologics and Enabling Technologies, $107.4M, down 1.1%
- Cash $86.9M vs $85.1M at December 31, 2025; nine-month operating cash flow $(23.5)M
- $65.0M Term B Loan funded; FDA reclassification headwind, heightened competition and pricing pressure for bone stimulators
Risk Factors
- Regulatory risk: FDA reclassification from Class III to Class II lowers entry barriers for bone growth stimulators
- Competitive risk: New entrants could create pricing pressure and erode Orthofix’s market share
- Operating risk: Higher research, clinical, marketing, and surveillance spending could reduce margins
- Market risk: Increased competitor promotion could reduce demand for Orthofix products
AI summary of the OFIX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor-relations presentation designated for use with investors and analysts through December 31, 2026
- Exhibit 99.2 likely outlines Orthofix’s corporate narrative, strategy, and investor messaging for fiscal 2026
Item 2.02: Results of Operations and Financial Condition
- Q3 results covered the period ended September 30, 2026, with detailed financial figures contained in Exhibit 99.1
- Management emphasizes adjusted EBITDA, free cash flow, constant-currency sales and adjusted earnings for operating performance analysis
Item EX-99.1: Item EX-99.1
- Q3 net sales $207.9M, up 1.1% reported, while pro forma constant-currency growth reached 2.3%
- Spine growth weakened to 0.9%, offset by Limb Reconstruction growth of 8.5% and Therapeutic Solutions growth of 4.5%
Item EX-99.2: Item EX-99.2
- Q3 2026 sales $207.9M, up 2% year over year constant currency, with Limb Reconstruction +9.4% and Therapeutic Solutions +4.5%
- U.S. Spine sales fell 4.3%, reflecting market softness, supplier delays, inventory constraints and instrument-set shortages
Item EX-99.1: Item EX-99.1
- Q2 net sales $210.9M, up 3.8% reported and 4.7% pro forma constant currency, supporting improved operating momentum
- Global Limb Reconstruction grew 13.2%, while Global Spine increased 3.5% pro forma, offsetting weaker portfolio areas
Item 2.02: Results of Operations and Financial Condition
- Q2 results for quarter ended June 30, 2026 announced August 5, 2026, with detailed figures in Exhibit 99.1
- Management emphasizes adjusted EBITDA, excluding merger, M6, restructuring, litigation, acquisition and employee transition costs
Item 7.01: Regulation FD Disclosure
- Investor relations presentation planned for use with investors and analysts through fiscal 2026
- Exhibit 99.2 likely contains the company’s current investor messaging and key performance materials
Item EX-99.2: Item EX-99.2
- Q2 2026 net sales $210.9M, up 5% YoY pro forma constant currency
- Adjusted EBITDA $20.1M, 10% margin, versus $20.6M in Q2 2025
Item 7.01: Regulation FD Disclosure
- CMS withdrew reimbursement changes for non-invasive bone growth stimulators effective May 18, 2026
- Medicare billing for HCPCS codes E0747, E0748 and E0760 returns to pre-reclassification treatment
AI summaries of OFIX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OFIX
Don't miss the next OFIX filing
- Alerts as it files. A push when OFIX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OFIX, by share count.
- Ask anything. An AI agent that reads every OFIX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Juniper Investment Company, LLC | Buy | Nov 11, 2026 | 14,803 | $7.04 |
| Juniper Investment Company, LLC | Buy | Nov 9, 2026 | 675,000 | $7.41 |
| Fisher Patrick | Sell | Nov 2, 2026 | 150 | $9.07 |
| Fisher Patrick | Sell | Oct 1, 2026 | 150 | $9.44 |
| Juniper Investment Company, LLC | Sell | Sep 21, 2026 | 190,000 | $8.86 |
| Juniper Investment Company, LLC | Buy | Sep 21, 2026 | 190,000 | $8.86 |
| Juniper Investment Company, LLC | Buy | Sep 18, 2026 | 120,000 | $8.74 |
| Juniper Investment Company, LLC | Sell | Sep 18, 2026 | 120,000 | $8.74 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $746.6M | $799.5M | $822.3M |
| Gross Profit | - | $545.9M | $566.0M |
| Operating Income | - | -$84.6M | -$81.4M |
| Net Income | - | -$126.0M | -$92.2M |
| Gross Margin | - | 68.3% | 68.8% |
| Op. Margin | - | -10.6% | -9.9% |
| Net Margin | - | -15.8% | -11.2% |
| Balance Sheet | |||
| Total Assets | $925.3M | $893.3M | $850.6M |
| Equity | $598.7M | $503.1M | $450.0M |
| ROE | - | -25.0% | -20.5% |
| Per Share | |||
| EPS | - | $-3.30 | $-2.33 |
| Cash Flow | |||
| Operating CF | - | $25.8M | $33.3M |
| CapEx | $60.3M | - | - |
Source: XBRL data in Orthofix Medical Inc. (OFIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OFIX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $111.9M |
| Q2 2026 | 25 | $103.8M |
| Q1 2026 | 23 | $117.2M |
| Q4 2025 | 23 | $160.0M |
| Q3 2025 | 25 | $163.7M |
| Q2 2025 | 26 | $124.0M |
| Q1 2025 | 22 | $89.7M |
| Q4 2024 | 18 | $83.8M |
- BlackRock+536.8K (+16%)
- Morgan Stanley+302.3K (+102%)
- Goldman Sachs Group+154.0K (+35%)
- Bank of America Corp+112.6K (+39%)
- Millennium Management+87.3K (+10%)
- AQR Capital Management−236.1K (-27%)
- Dimensional Fund Advisors−59.8K (-8%)
- Vanguard Capital Management LLC−28.4K (-2%)
- Wells Fargo & Co−26.0K (-76%)
- Renaissance Technologies LLC−16.9K (-17%)
- FMR LLC (Fidelity)−265.5K
- Citadel Advisors LLC−49.4K
- Two Sigma Investments−10.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OFIX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | May 29, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
OFIX SEC filings: frequently asked questions
Are OFIX insiders buying or selling?
In the last 90 days, Orthofix Medical Inc. (OFIX) officers, directors and 10% owners reported 4 open-market purchases worth $7.8 million by 1 insider and 5 open-market sales worth $2.7 million by 2 insiders on Form 4, a net purchase of $5.1 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OFIX stock?
As of September 30, 2026, the largest Orthofix Medical Inc. (OFIX) holders among the 13F filers tracked by SignalX were BlackRock ($36.4 million), Vanguard Capital Management LLC ($16.0 million), State Street Corp ($9.4 million), Millennium Management ($8.9 million), Dimensional Fund Advisors ($6.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OFIX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Orthofix Medical Inc. (OFIX) reported revenue of $822.3 million (up 2.9% from FY2024) and a net loss of $92.2 million. Diluted EPS was -$2.33. The figures come from the XBRL data in the 10-K.
What did OFIX report in its latest 8-K?
Orthofix Medical Inc. (OFIX) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Investor-relations presentation designated for use with investors and analysts through December 31, 2026.
What are the latest OFIX SEC filings?
Orthofix Medical Inc. (OFIX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.
What is OFIX's SEC CIK number?
Orthofix Medical Inc. (OFIX)'s SEC Central Index Key (CIK) is 884624. EDGAR lists every OFIX filing under that number.
Ask anything about OFIX
The research agent reads OFIX's filings, financials, insider trades and 13F holders, then answers with sources.